Triple Therapy Is the Foundation. Smoking Cessation Is the Disease-Modifier.
November 12, 2026

A clinical brief for referring providers — week 3 of a 4-part series on asthma-COPD overlap.
A question before the clinical note: A 58-year-old woman with lifelong asthma and a 15 pack-year history now has post-BD FEV1/FVC of 0.62 that no longer normalizes. She remains symptomatic on medium-dose ICS-LABA. Which intervention has the greatest potential to modify her disease trajectory?
a) Adding a leukotriene receptor antagonist b) Smoking cessation c) Switching ICS to a different molecule d) Starting N-acetylcysteine e) Reducing the ICS dose
That patient is the asthma-predominant side of ACO: long-standing asthma in a smoker that has developed persistent, fixed airflow limitation. The next step is to add a LAMA and step to triple therapy — never to reduce or stop the ICS — and to keep reinforcing smoking cessation, the key modifiable driver.
The foundation
ACO patients were historically excluded from therapeutic trials, so treatment is extrapolated from asthma and COPD data and guided by treatable traits. Two things hold throughout: ICS plus long-acting bronchodilation is always required, and many patients do best on triple ICS-LABA-LAMA, available as a single inhaler. Titrate the ICS dose to severity and to the eosinophilic component.
When asthma features are present, the ICS stays. Step up by adding a LAMA; never step down by reducing or stopping the ICS.
Add-ons by treatable trait
Eosinophilic or high-IgE, severe — Consider biologics — anti-IgE, anti-IL5/5Rα, anti-IL4Rα, anti-TSLP. Extrapolated from severe asthma; GOLD now endorses biologics for eosinophilic COPD with T2 inflammation
Neutrophilic, COPD-predominant, exacerbating — Consider a macrolide such as azithromycin, roflumilast (a PDE4 inhibitor), or N-acetylcysteine
Fixed obstruction, hyperinflation, little inflammation — Maximize long-acting bronchodilation
Mucus hypersecretion — Mucolytics or expectorants; macrolides
Always, alongside the inhalers
Smoking cessation, and avoidance of relevant allergens and noxious exposures
Pulmonary rehabilitation
Vaccination — influenza, pneumococcal, COVID-19, RSV
Comorbidity management — obesity, depression, cardiovascular and metabolic disease
Patient education and self-management
Refer the patient who keeps exacerbating
Biologic phenotyping, and the add-on decision when triple therapy is not enough — send them to the Chest & Sleep Team.
Call (847) 860-7250.
Sources: GINA 2026; GOLD 2026; Leung & Sin, Chest 2022; Mekov et al., Int J COPD 2021.
Abbreviations: ACO, asthma-COPD overlap. ICS, inhaled corticosteroid. LABA, long-acting beta-agonist. LAMA, long-acting muscarinic antagonist. BD, bronchodilator. FEV1/FVC, air forced out in the first second divided by the total. IgE, immunoglobulin E. T2, type-2 inflammation. TSLP, thymic stromal lymphopoietin. PDE4, phosphodiesterase-4.
The answer
Smoking cessation — the single most important disease-modifying intervention. Adding a LAMA (triple therapy) is the right pharmacologic step, but the ICS should never be reduced or stopped when asthma features are present.
